Serum Soluble Endoglin and Matrix Metalloproteinase 14 With Elisa Method in Early/Late-onset Preeclampsia
Serum Soluble Endoglin and Matrix Metalloproteinase 14 With Elisa Method in Early/Late-onset Preeclampsia
Objective: Defective placentation and inadequate trophoblastic invasion have an important
 place in the aetiology of preeclampsia (PrE). Trophoblasts invade the maternal decidua and
 remodel spiral arteries with matrix metalloproteinase-14 (MMP-14). To the best of our
 knowledge, studies of MMP-14 protein levels of PrE patients' sera remain unpublished. This
 study aims to investigate the value of serum MMP-14 and soluble endoglin (s-ENG) in PrE
 patients and healthy controls.

 Methods: The study was conducted with 30 late-onset preeclampsia patients (L-PrE) as group1
 (gestational age≥34 weeks), 33 patients with normal pregnancies as group2 (gestational age≥34
 weeks), 31 early-onset preeclampsia patients (E-PrE) as group3 (gestational age<34 weeks),
 and 31 patients with normal pregnancies as group 4 (gestational age<34 weeks). Serum MMP-14
 and s-ENG levels measured by ELISA were compared.
The study was conducted at Cengiz Gokcek Women's and Children's Hospital, Gaziantep, Turkey
 at department of obstetrics and gynecology between date of January 2018 and December 2018.
 The study protocol was designed according to the Declaration of Helsinki, and the
 institutional ethical review board of Gaziantep University approved the study (Reference
 number: 2018/91). One hundred twenty-five women enrolled in the study in four groups. The
 investigators consecutively recruited 61 pregnancies complicated with preeclampsia, and 64
 healthy pregnancies will select for the control group. All participiants gave their oral and
 written informed consent before their inclusion in the study.
Inclusion Criteria:

 -  preeclampsia

 -  healthy pregnancy

 Exclusion Criteria:

 -  pregnant women with any systemic condition (such as chronic hypertension, diabetes
 mellitus, thyroid diseases, liver and kidney diseases)

 -  women with a history of drug use throughout pregnancy

 -  history of medication for PE treatment at the time of first admission

 -  patients who had fetal congenital abnormalities or genetic syndromes

 -  multiple gestations

 -  active labour